Unraveling galectin-1 as a novel therapeutic target for cancer.
Cancer Treat Rev
; 40(2): 307-19, 2014 Mar.
Article
em En
| MEDLINE
| ID: mdl-23953240
Palavras-chave
Angiogenesis; CDC42; Cell transformation; ECM; ERK; Gal-1; Galectin-1; HIF1α; Invasion; JNK; MEK; MMP; Metastasis; NFkB; NRP1; Novel target; PI3K; PKC; ROS; Ras homolog gene family, member A; RhoA; Therapeutic application; VEGFR2; c-Jun NH2-terminal kinases; cell division control protein 42 homolog; extracellular matrix; extracellular-signal-regulated kinase; galectin-1; hypoxia-inducible factor 1-alpha; matrix metalloproteinase; mitogen-activated protein kinase kinase (MAP2K); neuropilin-1; nuclear factor kappa B; phosphoinositide-3-kinase; protein kinase C; reactive oxygen species; tPA; tissue plasminogen activator; vascular endothelial growth factor receptor 2
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Galectina 1
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Cancer Treat Rev
Ano de publicação:
2014
Tipo de documento:
Article